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Objective 
 
To assess the efficacy and safety of sorafenib dose escalation in metastatic renal cell carcinoma 
(mRCC). 
Patients and Methods 
 
Intra-patient dose escalation may enhance the clinical benefit of targeted anticancer agents in 
metastatic disease. In this non-randomised, open-label, Phase 2b study, treatment-naïve patients 
with mRCC were initially treated with the standard oral sorafenib dose [400 mg twice daily (BID)]. 
Two dose escalations were planned, each 200 mg BID after 28 days at the prior level. Dose 
reductions, interruptions, or delayed escalations were used to manage adverse events (AEs). The 
primary endpoint was objective response rate (ORR) in the modified intent-to-treat (mITT) 
population, which comprised patients with ≥6 months of treatment including ≥4 months of therapy 
at their highest tolerated dose. Secondary endpoints included progression-free survival (PFS) and 
safety. 
Results 
 
In all, 83 patients received sorafenib. The dose received for the longest duration was 400, 600, and 
800 mg BID in 48.2%, 15.7%, and 24.1% of patients, respectively. The ORR was 44.4% [n = 8/18; 95% 
confidence interval (CI) 21.5–69.2] and 17.9% (n = 12/67; 95% CI 9.6–29.2) in the mITT and ITT 
populations, respectively. The median (95% CI) PFS was 7.4 (6.0–11.7) months (ITT). The most 
common AEs of any grade were hand–foot skin reaction (66.3%) and diarrhoea (63.9%). 
Conclusion 
 
Sorafenib demonstrated clinical benefit in treatment-naïve patients with mRCC. However, relatively 
few patients could sustain doses of >400 mg BID. There was evidence that, where tolerated, 
escalation from the standard sorafenib dose may have enhanced clinical benefit. However, this study 
does not support dose escalation for most patients with treatment-naïve mRCC. Alternative 
protocols for sorafenib dose escalation could be explored. 
Introduction 
 
The advent of molecularly targeted agents brought welcome advances in the treatment of 
metastatic RCC (mRCC). However, more effective approaches to this ultimately incurable disease are 
needed. One strategy is intra-patient dose escalation of agents that have demonstrated efficacy and 
tolerability. 
 
Sorafenib, an oral inhibitor of several kinases involved in tumour angiogenesis and cell proliferation, 
is approved in differentiated thyroid carcinoma, hepatocellular carcinoma, and advanced/mRCC [1-
6]. The pivotal TARGET trial in patients pre-treated with cytokine therapy demonstrated efficacy of 
sorafenib 400 mg twice daily (BID); this subsequently became the approved regimen [3-6]. 
 
Attempts to enhance clinical outcome investigated sorafenib doses >400 mg BID [7-9]. A Phase 2 
study in mRCC in which ~50% of patients had received prior systemic therapy but no tyrosine kinase 
inhibitor escalated the sorafenib dose at 28-day intervals to 600 mg BID [in 92.9% of patients (n = 
39/42)], then 800 mg BID [in 73.8% of patients (n = 31/42)] [9]. The objective response rate (ORR) 
was 47.7% (n = 21/44) and median progression-free survival (PFS) was 8.4 months [9]. These 
outcomes compared favourably with those of TARGET. 
 
Further investigation of sorafenib dose escalation was therefore warranted. In the present study, we 
report the efficacy, safety, and tolerability from an open-label, Phase 2b study of planned sorafenib 
dose escalation in treatment-naïve patients with mRCC. 
Patients and Methods 
 
Study Design and Patients 
 
This non-randomised, open-label, uncontrolled, international, multicentre, Phase 2b study 
(ClinicalTrials.gov NCT00618982) recruited patients aged ≥18 years with: histologically/cytologically 
confirmed metastatic clear cell RCC; no prior systemic therapy for RCC; Eastern Cooperative 
Oncology Group performance status (ECOG PS) 0 or 1; intermediate or good prognosis according to 
the Memorial Sloan-Kettering Cancer Center scale [10]; ≥1 measurable lesion by CT or MRI according 
to Response Evaluation Criteria in Solid Tumors (RECIST) v1.0; life expectancy of ≥12 weeks; prior 
nephrectomy; and adequate bone marrow, liver, and renal function assessed within 7 days prior to 
study treatment. Prior palliative radiotherapy to non-targeted metastatic lesions according to RECIST 
was permitted. 
 
Exclusion criteria included: history of cardiac disease (congestive heart failure >New York Heart 
Association class 2); acute coronary disease (myocardial infarction >6 months before study entry was 
allowed); cardiac arrhythmias requiring anti-arrhythmic therapy (β-blockers or digoxin were 
permitted); or uncontrolled hypertension; history of HIV infection or chronic hepatitis B or C; active 
clinically serious infections >Grade 2; symptomatic metastatic brain or meningeal tumours; seizure 
disorders requiring medication; history of organ allograft; evidence or history of bleeding diathesis; 
deep vein thrombosis and/or pulmonary embolus within 12 months of treatment initiation; delayed 
healing of wounds, ulcers, or bone fractures; pre-existing thyroid abnormality; undergoing renal 
dialysis; previous or concurrent cancer distinct in primary site or histology from mRCC (except 
cervical carcinoma in situ, treated basal cell carcinoma, non-muscle-invasive bladder cancer, or any 
cancer curatively treated >3 years prior to study entry); pregnancy/breastfeeding; inability to 
swallow oral medications; any prior systemic anticancer therapy; major surgery within 4 weeks prior 
to study entry; radiotherapy within 3 weeks of study drug initiation; biological response modifiers, 
e.g. granulocyte colony stimulating factor (G-CSF), within 3 weeks prior to study entry; or autologous 
bone marrow transplant or stem cell rescue within 4 months of study entry. 
 
All patients provided written informed consent, and study approval was obtained from ethics 
committees (Table S1). The study was conducted in accordance with the World Medical Association 
Declaration of Helsinki, the International Conference on Harmonization guideline E6 for Good 
Clinical Practice, and local ethical and legal requirements. 
Treatment 
 
The initial dose was oral sorafenib 400 mg BID. Two dose escalations were planned: to 600 mg BID 
after 28 days at the starting dose, then to 800 mg BID after another 28 days. The occurrence of any 
symptomatic adverse event (AE) ≥Grade 3 (except nausea or vomiting) prevented dose escalation 
until the event resolved to Grade 1. Treatment continued until disease progression, unacceptable 
toxicity, withdrawal of consent, investigator's decision, or study end. Dose delays or reductions to 
400 or 200 mg daily were allowed to manage AEs (200 mg daily dose given as 400 mg every other 
day or 200 mg once daily). Dose modification or delay due to hypertension or dermatological, 
haematological, and non-haematological AEs was permitted according to specific criteria (Tables S2–
S6). 
 
Concomitant therapies were allowed: palliative radiotherapy to ≤10% of the patient's bone marrow 
provided that a target lesion was not irradiated and there was no progressive disease; G-CSF and 
other haemopoietic growth factors to manage acute toxicity, and secondary (not primary) 
prophylaxis with erythropoietin, providing these did not replace a required sorafenib dose 
reduction; other palliative/supportive care, including bisphosphonates. 
Assessments 
 
Efficacy analyses were performed in the intent-to-treat (ITT) population (all patients who received ≥1 
sorafenib dose and had ≥1 valid efficacy evaluation post-baseline). The primary endpoint was the 
ORR (complete or partial response) at 6 months in patients with ≥4 months of therapy at the highest 
tolerated dose; this was analysed in the modified ITT (mITT) population (subgroup treated for ≥6 
months with ≥4 months at their highest tolerated sorafenib dose). Secondary endpoints included 
PFS, time to progression (TTP), safety and tolerability, and pharmacokinetics. The safety population 
included all patients who received ≥1 sorafenib dose and for whom post-baseline data were 
available. 
 
Tumour response and progression were assessed by central, independent, radiological review every 
8 weeks using RECIST v1.0 [11]. Objective responses or stable disease were confirmed at the next 
scheduled scan. PFS was assessed from the start of study medication to the first radiological or 
clinical progression, or death. The TTP was measured from the start of study medication to the first 
radiological or clinical progression. AEs were assessed using the National Cancer Institute's Common 
Terminology Criteria for Adverse Events v3.0 [12]. Pharmacokinetic samples (6 mL) were collected 
on day 28 of the first completed cycle at each dose level at pre-dose and 2, 4, 6, 8, 10, and 12 h post-
dose time points. Samples to measure plasma levels of sorafenib and its metabolites (M2, M4, and 
M5) were drawn on day 28 of the first cycle at each dose level. 
Determination of Sample Size 
 
A sample size of 80 patients was chosen in order to get a 95% CI ± 10% for a response rate of ~30% 
(nQuery version 6.1 module POCO-1). 
Results 
 
Patients 
 
The first patient was treated on 4 February 2008; the last patient visit was 13 January 2011; and the 
data collection limit was 6 August 2012. In all, 89 patients enrolled at 19 centres in France, UK, 
Germany, Italy, and Poland. Of these, 83 patients received sorafenib and were included in the safety 
population (Fig. S1). The ITT and mITT populations included 67 and 18 patients, respectively. Of the 
49 ITT patients excluded from the mITT population, 32 (65.3%) and 14 (28.6) discontinued sorafenib 
due to disease progression and toxicity, respectively (Table S7). 
 
The ITT subgroups according to the sorafenib dose received for the longest duration showed broadly 
similar baseline demographics (Table 1). The mean time since diagnosis was 2.0, 0.7, and 2.3 years 
with 400, 600, and 800 mg BID dose, respectively. 
 
Table 1. Baseline demographic and clinical characteristics 
 
 
 
 
 
  
Safety 
population 
ITT population 
Overall (n= 
83) 
Overall 
(n = 67) 
400 mg 
BID*(n = 
25) 
600 mg 
BID*(n = 
12) 
800 mg 
BID*(n = 
20) 
Median 
(range) age, 
years 
61 (33–80) 62 (33–
80) 
64 (44–
80) 
59 (33–
78) 
57 (39–
72) 
Male, n (%) 
or n/N 
54 (65.1) 44 
(65.7) 
15 (60.0) 9/12 15 (75.0) 
ECOG PS, n (%) or n/N 
0 49 (59.0) 40 
(59.7) 
14 (56.0) 7/12 13 (65.0) 
1 34 (41.0) 27 
(40.3) 
11 (44.0) 5/12 7 (35.0) 
Disease stage, n (%) or n/N 
III 1 (1.2) 1 (1.5) 0 0 0 
IV 82 (98.8) 66 
(98.5) 
25 
(100.0) 
12/12 20 
(100.0) 
Clinical/radiological status at entry, n (%) or n/N 
Stable disease 15 (18.1) 12 
(17.9) 
4 (16.0) 2/12 2 (10.0) 
Progressive 
disease 
68 (81.9) 55 
(82.1) 
21 (84.0) 10/12 18 (90.0) 
 Mean (SD) 
time since 
initial 
diagnosis†, 
years 
2.1 (3.1) 2.0 (3.1) 2.0 (3.9) 0.7 (0.7) 2.3 (3.0) 
Number of metastatic lesions, n (%) or n/N 
1 14 (16.9) 0 0 0 0 
≥2 69 (83.1) 67 
(100.0) 
25 
(100.0) 
12/12 20 
(100.0) 
Metastatic sites, n (%) or n/N 
Lung 53 (63.9) 51 
(76.1) 
20 (80.0) 11/12 14 (70.0) 
Lymph nodes 33 (39.8) 33 
(49.3) 
10 (40.0) 7/12 11 (55.0) 
Liver 25 (30.1) 25 
(37.3) 
8 (32.0) 4/12 9 (45.0) 
Bone 16 (19.3) 16 
(23.9) 
9 (36.0) 2/12 3 (15.0) 
Prior therapy for RCC, n (%) or n/N 
Surgery 83 (100.0) 67 
(100.0) 
25 
(100.0) 
12/12 20 
(100.0) 
Radiotherapy 12 (14.5) 10 
(14.9) 
4 (16.0) 3/12 1 (5.0) 
Systemic 
anticancer 
therapy‡ 
3 (3.6) 2 (3.0) 1 (4.0) 0/12 0 
*Dose taken for the longest duration while in the study; 10 patients treated at doses <400 mg BID 
are not included because of small sample sizes; †These data were unavailable for one patient in each 
of the overall safety population (n = 82) and the overall ITT population (n = 66) [in the 400 mg BID 
group (n = 24)]; ‡Three patients received prior anticancer therapy with endocrine therapy (n = 2) and 
an immunostimulant (n = 1). These treatments were not considered protocol violations. 
 
Treatment Duration and Doses Received 
 
In the safety population, the median (range) treatment duration was 225 (7–1072) days, mean (SD) 
daily dose was 902 (364) mg/day, and the median (range) duration of follow-up was 252 (14–1 071) 
days. The maximum dose reached was 400 mg BID in 31 (37.3%) patients, 600 mg BID in 12 (14.5%) 
patients, and 800 mg BID in 40 (48.2%) patients. The dose [median (range) duration] received for the 
longest duration was 400 mg BID in 40 (48.2%) patients [29.5 (7–855) days]; 600 mg BID in 13 
(15.7%) patients [164 (62–681) days]; 800 mg BID in 20 (24.1%) patients [177.5 (56–956) days]; 400 
mg daily in seven (8.4%) patients [434 (122–764) days]; and 400 mg every other day in three (3.6%) 
patients [332 (136–675) days]. 
Efficacy 
 
In the mITT population, all patients had partial response (n = 8/18) or stable disease (n = 10/18) 
(Table 2A). The primary efficacy endpoint, the ORR, was 44.4% (95% CI 21.5–69.2). In the ITT 
population, the ORR was 17.9% (n = 12/67) (95% CI 9.6‒29.2) (Table 2B). Tumour shrinkage occurred 
in 18/25 (72.0%), (9/12) 75.0%, and 17/20 (85.0%) of patients in the 400, 600, and 800 mg BID 
groups, respectively (Fig. 1). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2. Tumour response and progression-free survival (PFS) in the modified intent-to-treat (mITT) 
(A) and ITT (B) populations, assessed by independent central review 
 
 
  Overall 
200 
mg 
Daily*,
† 
400 mg 
OD* 
400 mg 
BID* 
600 mg 
BID* 
800 mg 
BID* 
(A) mITT 
N 18 2 5 1 2 8 
Partial 
response, n (
%) or n/N 
8 (44.4) 0/2 2/5 1/1 1/2 4/8 
Stable 
disease, n (%
) or n/N 
10 (55.6) 2/2 3/5 0/1 1/2 4/8 
Progressive 
disease, n (%
) or n/N 
0 0/2 0/5 0/1 0/2 0/8 
Response 
rate‡, % 
(95% CI) 
44.4 
(21.5−69.
2) 
0 
(0−84.
2) 
40.0 
(5.3−85.
3) 
100.0 
(2.5−100.
0) 
50.0 
(1.3−98.
7) 
50.0 
(15.7−84.
3) 
(B) ITT 
N 67 3 7 25 12 20 
Partial 
response, n (
%) or n/N 
12 (17.9) 0/3 2/7 1 (4.0) 2/12 7 (35.0) 
Stable 46 (68.7) 3/3 5/7 15 (60.0) 10/12 13 (65.0) 
  Overall 
200 
mg 
Daily*,
† 
400 mg 
OD* 
400 mg 
BID* 
600 mg 
BID* 
800 mg 
BID* 
disease, n (%
) or n/N 
Progressive 
disease, n (%
) or n/N 
9 (13.4) 0/3 0/7 9 (36.0) 0/12 0 
Response 
rate‡, % 
(95% CI) 
17.9 
(9.6−29.2
) 
0 (0–
70.8) 
28.6 
(3.7–
71.0) 
4.0 
(0.1−20.4
) 
16.7 
(2.1−48.
4) 
35.0 
(15.4−59.
2) 
Median 
(95% CI) PFS, 
months 
7.4 
(6.0−11.7
) 
ND§ ND§ 3.7 
(1.8−9.7) 
7.4 
(6.3−12.
0) 
8.5 
(5.5−14.9
) 
Progression-
free at 6 
months, % 
or n/N 
62.3 ND§ ND§ 49.1 9/12 58.6 
Progression-
free at 12 
months, % 
or n/N 
33.4 ND§ ND§ 24.6 3/12 39.1 
 
 
 
No complete responses were recorded. OD, once daily; ND, not determined. *Dose taken for the 
longest duration while in the study. †200 mg daily dose was received as 400 mg every other day or 
200 mg once daily. ‡Response rate defined as complete response + partial response. §These data 
were not determined due to the small sample sizes for these subgroups. 
 
 
 
 
 
 
 
Figure 1.  
Maximum tumour shrinkage in individual patients (% change from baseline in target lesions by 
independent assessment) according to the dose received for the longest duration in the study 
[intent-to-treat (ITT) population]. Dotted line represents the threshold for response using Response 
Evaluation Criteria in Solid Tumors (RECIST) v1.0. Maximum tumour shrinkage for patients in the ITT 
population who received doses of 400, 600, or 800 mg/day twice daily (BID) for the longest duration 
while in the study were included as long as the independent central reviewer could establish a best 
response. 
 
 
In the ITT population, the overall median PFS was 7.4 months (95% CI 6.0‒11.7) (Table 2B and Fig. 2 
[3]); 62.3% and 33.4% of patients were progression free at 6 and 12 months, respectively. The 
median (95% CI) PFS was 3.7 (1.8–9.7), 7.4 (6.3–12.0), and 8.5 (5.5–14.9) months for the 400, 600, 
and 800 mg BID groups, respectively (ITT). The TTP results were identical to those for PFS, because 
no deaths occurred before disease progression was observed. 
 
 
 
 
 
 
Figure 2. 
 
Kaplan–Meier graph showing progression-free survival (PFS) by independent central assessment 
according to the dose received for the longest duration in the study [intent-to-treat (ITT) 
population]. The PFS curve from the Phase 3 trial of sorafenib for treatment of metastatic renal cell 
carcinoma (mRCC) (TARGET) is shown for comparison [3]. 
 
 
Safety 
All 83 patients reported at least one treatment-emergent AE (TEAE). The most common TEAEs of any 
grade were hand–foot skin reaction (HFSR; 66.3%), diarrhoea (63.9%), rash/desquamation (56.6%), 
fatigue (54.2%), and hypertension (48.2%) (Table 3). One patient (1.2%) had Grade 2 proteinuria. 
Most patients (90.4%; n = 75) had at least one ≥Grade 3 event. The most common Grade 3 events 
were HFSR (25.3%), fatigue (15.7%), hypophosphataemia (15.7%), and rash/desquamation (13.3%) 
(Table 3). Two patients had Grade 3 renal failure. Apart from hyponatraemia and elevated lipase 
[both two patients (2.4%)], Grade 4 events occurred in individual patients only (Table 3). 
Table 4 summarises the TEAEs by dose at first occurrence. Most patients (91.6%) had their first AE at 
400 mg BID. 
Table 3. Incidence of TEAEs by worst grade, occurring in >10% patients at any grade, >5% patients at 
Grade 3, or >2% patients at Grade 4 (safety population, N = 83) 
 
 
 
 
Adverse event 
n (%) 
Any grade Grade 3 Grade 4 
Any event 83 (100.0) 61 (73.5) 13 (15.7) 
HFSR 55 (66.3) 21 (25.3) 0 
Diarrhoea 53 (63.9) 10 (12.0) 1 (1.2) 
Rash/desquamation 47 (56.6) 11 (13.3) 0 
Fatigue 45 (54.2) 13 (15.7) 1 (1.2) 
Hypertension 40 (48.2) 5 (6.0) 0 
Alopecia 36 (43.4) 0 0 
Mucositis (functional/symptomatic), oral 
cavity 
27 (32.5) 0 0 
Dry skin 23 (27.7) 1 (1.2) 0 
Nausea 22 (26.5) 0 0 
Anorexia 21 (25.3) 1 (1.2) 0 
Hypophosphataemia 17 (20.5) 13 (15.7) 1 (1.2) 
Vomiting 16 (19.3) 1 (1.2) 0 
Pruritus 15 (18.1) 1 (1.2) 0 
Fever 14 (16.9) 0 0 
Weight loss 14 (16.9) 1 (1.2) 0 
Adverse event 
n (%) 
Any grade Grade 3 Grade 4 
Dyspnoea 13 (15.7) 1 (1.2) 0 
Haemoglobin 12 (14.5) 1 (1.2) 0 
Hypothyroidism 12 (14.5) 0 0 
Neuropathy: sensory 12 (14.5) 0 0 
Pain, abdomen (not otherwise specified) 11 (13.3) 1 (1.2) 0 
Taste alteration 11 (13.3) 0 0 
Voice changes 11 (13.3) 0 0 
Lipase 10 (12.0) 10 (12.0) 2 (2.4) 
Pain, back 10 (12.0) 3 (3.6) 0 
Constipation 9 (10.8) 0 0 
Alanine aminotransferase 7 (8.4) 5 (6.0) 0 
Hyponatraemia 5 (6.0) 3 (3.6) 2 (2.4) 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4. Incidence of TEAEs (any grade, occurring in >10% of patients in any category) by dose at first 
occurrence (safety population) 
 
 
 
 
AE 
n/N or n (%) 
200 mg 
Daily* (n = 
10) 
400 
mg OD 
(n = 
38) 
400 
mg 
BID 
(n = 
83) 
600 
mg 
BID 
(n = 
52) 
800 
mg 
BID 
(n = 
40) 
Any event 1/10 5 
(13.2) 
76 
(91.6) 
0 1 (2.5) 
HFSR 0/10 3 (7.9) 43 
(51.8) 
5 (9.6) 4 
(10.0) 
Rash/desquamation 1/10 1 (2.6) 38 
(45.8) 
5 (9.6) 2 (5.0) 
Fatigue 2/10 2 (5.3) 29 
(34.9) 
4 (7.7) 5 
(12.5) 
Hypertension 2/10 4 
(10.5) 
29 
(34.9) 
2 (3.8) 2 (5.0) 
Diarrhoea 1/10 3 (7.9) 21 
(25.3) 
19 
(36.5) 
9 
(22.5) 
Oral mucositis 
(functional/symptomatic) 
1/10 2 (5.3) 19 
(22.9) 
4 (7.7) 1 (2.5) 
Alopecia 1/10 5 
(13.2) 
16 
(19.3) 
9 
(17.3) 
5 
(12.5) 
Dry skin 1/10 1 (2.6) 13 3 (5.8) 5 
AE 
n/N or n (%) 
200 mg 
Daily* (n = 
10) 
400 
mg OD 
(n = 
38) 
400 
mg 
BID 
(n = 
83) 
600 
mg 
BID 
(n = 
52) 
800 
mg 
BID 
(n = 
40) 
(15.7) (12.5) 
Hypophosphataemia 0/10 1 (2.6) 13 
(15.7) 
3 (5.8) 0 
Nausea 2/10 2 (5.3) 10 
(12.0) 
3 (5.8) 5 
(12.5) 
Pruritus 0/10 2 (5.3) 10 
(12.0) 
2 (3.8) 0 
Vomiting 0/10 1 (2.6) 8 (9.6) 2 (3.8) 5 
(12.5) 
Anorexia 1/10 0 6 (7.2) 8 
(15.4) 
6 
(15.0) 
Weight loss 0/10 0 5 (6.0) 2 (3.8) 7 
(17.5) 
Hypocalcaemia 0/10 0 1 (1.2) 0 5 
(12.5) 
 
Data are ordered in decreasing incidence seen in the largest subgroup (400 mg BID). OD, once daily. 
*200 mg daily dose was received as 400 mg every other day or 200 mg OD. 
 
Serious TEAEs were reported in 44 (53.0%) patients and most were single occurrences. The most 
common serious TEAEs, each occurring in three (3.6%) patients, were fatigue, rash/desquamation, 
gastrointestinal (other), hyponatraemia, and intraoperative injury. 
 
Dose interruptions, reductions, and withdrawals due to AEs occurred in 69 (83.1%), 50 (60.2%), and 
36 (43.4%) patients, respectively. Dose interruptions or withdrawals occurred most frequently in 
patients receiving 400 mg BID vs other doses. 
 
One death was reported, due to cardiopulmonary failure, which was not considered to be related to 
sorafenib. Another death was reported >30 days after the last study drug dose due to 
cardiopulmonary failure caused by progressive RCC. In both cases, the sorafenib dose received for 
the longest duration was 400 mg BID. 
Pharmacokinetics 
 
No increase in exposure [area under the curve (AUC) or maximum plasma concentration (Cmax)] for 
sorafenib or its metabolites (M2, M4, and M5) was observed with increase in dose, indicating a lack 
of dose proportionality (Table S8). 
Discussion 
 
In the present open-label dose-escalation study, sorafenib showed apparent clinical benefit in the 
ORR and PFS in treatment-naïve patients with mRCC in the mITT population. The ORR for the mITT 
population (eight of 18 patients, 44.4%) compared favourably to that in other first-line sorafenib 
trials [3, 8, 13-17], and was similar to that in the Phase 2 dose-escalation study of Amato et al. [9] of 
47.7%. These observations suggest that mITT patients may have gained additional benefit from 
sorafenib dose escalation. However, these results should be interpreted cautiously due to small 
patient numbers and the fact that, by definition, the mITT population had tolerated sorafenib 
relatively well (≥4 months at the maximum tolerated dose) and had slow-growing tumours (stayed in 
the study for ≥6 months). The mITT population may only represent a small proportion of patients 
with mRCC. 
 
In the ITT population, the median PFS (7.4 months) and ORR (17.9%) fell within the ranges reported 
in Phase 2/3 studies of first-line standard-dose sorafenib in mRCC (median PFS 5.5–9.1 months; ORR 
5.2–30.0%) [3, 8, 13-17]. Therefore, the results of the present study do not support an improved 
benefit/risk ratio with sorafenib dose escalation up to 800 mg BID in mRCC compared to historical 
data with sorafenib 400 mg BID. However, comparison of ORR and PFS in different dose groups 
showed that patients who tolerated higher doses of sorafenib (>400 mg BID) appeared to have 
enhanced clinical benefit compared with those receiving doses of ≤400 mg BID. However, a 
meaningful comparison between the dosage groups is limited because the higher-dose groups were 
enriched with patients who tolerated sorafenib better and whose disease progressed later. 
 
Outcomes in the ITT population appeared inferior to those reported by Amato et al. [9], who 
followed a similar dose-escalation protocol [9]. This may reflect the fact that sorafenib therapy and 
dose escalation were less well tolerated in the present study. Of note, the numbers of Grade 3/4 AEs 
in the Amato et al. study were much lower, allowing a greater proportion of patients to reach and 
potentially benefit from the 800 mg BID dose. Patients in the Texan Amato et al. [9] study could have 
been more homogeneous, and different in anthropometric characteristics, compared with our 
international ITT population. 
 
Dosage groups for pharmacokinetics were not the same as for efficacy (dose received for the longest 
duration) or safety (dose at first occurrence). Rather, blood for pharmacokinetic analyses was 
collected on day 28 of the first cycle completed at each dose level. No apparent increase in sorafenib 
exposure was seen at higher doses. However, patients were not randomised into dose groups, there 
is large inter-patient variation in sorafenib exposure at the same dose, and incidence of Grade 3/4 
AEs has been associated with higher exposure [18, 19]. Patients with low sorafenib exposure may 
therefore have been over-represented in the high-dose groups, being less prone to severe AEs that 
precluded dose escalation. Further confounding interpretation of pharmacokinetic data, samples 
from patients receiving higher doses were taken at later time points than lower-dose samples, and 
sorafenib exposure declines over time [19, 20]. 
 
No new or unexpected toxicities arose in our present study. Most TEAEs first occurred with the 
starting dose of sorafenib, 400 mg BID, which is consistent with previous analyses showing that AEs 
with sorafenib tend to first occur early in treatment [21, 22]. Gastrointestinal disorders were the 
exception, most often starting with 600 or 800 mg BID. These findings should be interpreted 
cautiously given that patients were not randomised to dose groups. However, these observations 
are consistent with data from a sorafenib dose-escalation study in metastatic melanoma, where 
HFSR and hypertension correlated with exposure, whereas diarrhoea and anorexia correlated with 
dose level [23]. The small proportion of patients who could sustain the highest dose level and the 
need for frequent dose reductions and interruptions to manage AEs reflects the difficulties of 
generally implementing a dose-escalation schedule in this patient population. However, there may 
be value in exploring alternative protocols for sorafenib dose escalation, e.g., escalation to restore 
antitumour activity in patients whose disease progressed with reduced exposure, or regular 
monitoring of plasma concentrations and dose adjustment to maintain exposure over time [20, 24]. 
 
The present study assessed the use of scheduled intra-patient dose escalation to enhance response 
rates with sorafenib in patients with mRCC. We conclude that escalating the sorafenib dose from the 
standard 400 mg BID may have benefited individual patients able to tolerate this approach. 
However, the present study does not support this type of scheduled dose escalation for all patients 
with treatment-naïve mRCC. Alternative protocols for sorafenib dose escalation could be explored. 
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